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 Sarcopenia is associated with functional impairment and adverse outcomes. 
 Highly inflammatory cytokines are negatively related to muscle strength and mass. 
 Sarcopenia is associated with higher serum inflammatory parameters.  
 Chronic inflammation could play a role in sarcopenia.  
 
Abstract 
Inflammatory cytokines have been shown to prompt muscle wasting, ultimately stimulating protein 
catabolism and suppressing muscle synthesis. However, the possible association between 
inflammatory parameters and sarcopenia is poorly understood. We therefore aimed to summarize 
the current evidence about this topic with a meta-analysis of studies reporting serum inflammatory 
parameters in patients with sarcopenia vs. people without sarcopenia (controls). An electronic 
PubMed and Scopus search through to 09/01/2016 and meta-analysis of cross-sectional studies 
comparing serum levels of inflammatory cytokines between patients with sarcopenia and controls 
was made, calculating random-effects standardized mean differences (SMDs) ±95% confidence 
intervals (CIs) as the effect size. Out of 1370 initial hits, 17 studies with a total of 11249 
participants (3072 with sarcopenia and 8177 without) were meta-analysed. Sarcopenic participants 
had significantly higher levels of CRP (SMD=0.51; 95%CI 0.26, 0.77; p<0.0001; I2=96%) than 
controls. Conversely, serum IL6 levels were not significantly different (SMD=0.35; 95%CI: -0.19, 
0.89; p=0.21; I2=97%) in people with sarcopenia versus controls. Sarcopenic people did not have 
higher levels of TNF-than controls (SMD=0.28; 95%CI -0.26, 0.83; p=0.31; I2=97%). In 
conclusion, sarcopenia seems to be associated with elevated serum CRP levels; future longitudinal 
studies are needed to clarify this relationship. 
 






Inflammation is an adaptive response of the immune system triggered by a homeostatic imbalance, 
to restore functionality.  Whereas the acute inflammatory process induced by infection or tissue 
injury is clear, considerably less is known about the deleterious effects of chronic low-grade 
inflammation. The oxidative stress-induced redox imbalance and the sustained upregulation of pro 
inflammatory mediators are believed to act as the patho-physiological basis underpinning 
inflammatory disorders including cardiovascular diseases, cancer, diabetes, dementia and also 
sarcopenia [1]. 
According to the recent definitions of several working groups, sarcopenia is described as a 
syndrome characterized by a loss of muscle mass and strength with functional impairment and 
adverse outcomes [2], [3]. The age related muscle loss coincides with a micro and macro 
architecture disorganization of the entire muscle mass. For instance, the conversion of type II (fast) 
fibers to type I (slow) fibers and subsequent lipid infiltration, which translate into impairment of 
muscle power and a greatly increased risk of falls [4]. Several studies have shown that sarcopenic 
individuals are either three times more likely to fall or have an higher risk of death relative to non 
sarcopenic individuals [5], [6].  Moreover,  sarcopenia itself is associated with disability and 
hospitalization [7]. 
A substantial body of literature has demonstrated that inflammatory cytokines activate many of the 
molecular pathways involved in skeletal muscle wasting leading to an imbalance between protein 
synthesis and catabolism [8], [9]. High levels of inflammatory cytokines have been demonstrated to 
be negatively related to muscle strength and mass [10], [11]. However, the research considering 
whether their serum cytokine levels could represent a biological marker of sarcopenia is equivocal 
[12]. 
Therefore, we conducted a systematic review and meta-analysis of observational studies exploring 
the association between serum inflammatory parameters and sarcopenia.  We hypothesized that 





This systematic review was conducted following the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) criteria for the quality assessment of included studies [13] and 
the indications of Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
statement. [14] 
 
2.1 Search Strategy 
Two investigators (MS, CL) independently conducted an electronic literature search using PubMed 
and Scopus, without language restriction, from database inception until 09/01/2016. In PubMed, 
controlled vocabulary terms and the following keywords were used: ("sarcopenia"[All Fields]) 
AND (("inflammation"[MeSH Terms] OR "inflammation"[All Fields]) OR inflammatory[All 
Fields] OR IFN[All Fields] OR ("interferons"[MeSH Terms] OR "interferons"[All Fields] OR 
"interferon"[All Fields]) OR TNF[All Fields] OR "tumor necrosis factor"[All Fields] OR IL[All 
Fields] OR "interleukin"[All Fields] OR "TGF"[All Fields] OR ("apoptosis"[MeSH Terms] OR 
"apoptosis"[All Fields]) OR apoptotic[All Fields] OR antiapoptotic[All Fields] OR CRP[All Fields] 
OR "C-reactive protein"[All fields] OR ("cytokines"[MeSH Terms] OR "cytokines"[All Fields] OR 
"cytokine"[All Fields])). A similar search strategy was run in Scopus. Conference abstracts were 
also considered and at least 4 attempts were made to contact study authors for additional 
information. Reference lists of included articles and those relevant to the topic were hand-searched 
for identification of additional, potentially relevant articles.  
 
 
2.2 Study Selection 
Included were studies that (1) compared data on inflammatory parameters between participants with 
sarcopenia vs. those without, (2) reported on serum levels of inflammatory cytokines, and (3) 
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reported data about muscular mass assessed with Dual-energy X-ray Absorptiometry (DXA) , 
Magnetic Resonance Imaging (MRI) or bioimpendenziometry (BIA) and not only with body 
composition estimates (e.g. calf circumference). Studies were excluded if they (1) did not use clear 
diagnostic criteria for sarcopenia, (2) measured only in vitro parameters or used animal models, or 
(3) did not measure or did not report quantitative cytokine levels in both sarcopenic and no 
sarcopenic subjects.  
We also contacted authors asking for further information when: 1) data could not be meta-analyzed 
(i.e., no mean and standard deviation (SD) or equivalent for inflammatory parameters), 2) other 
relevant information was missing, 3) data about muscular mass were reported, but sarcopenia 
diagnosis no. At least 4 attempts were made with these Authors.   
Study data consisting of cytokine levels with SDs larger than three times the mean were excluded 
from the analyses, as we considered these to be overly skewed and unreliable. [15] 
 
2.3 Data Extraction 
Two authors (CT, SC) independently extracted data from the selected studies into a standardized 
Microsoft Excel spreadsheet. Any disagreement was resolved by consensus. The following 
information were extracted: i) study population characteristics (e.g., sample size, demographics); ii) 
clinical setting in which the study was performed; iii) parameters related to sarcopenia and 
inflammation (age, gender, body mass index) in sarcopenic and no sarcopenic subjects, iv) 




2.4 Assessment of study quality 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria [13] 
were used for the quality assessment of included studies. One Author made the assessment of 
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quality  (MS) and any discrepancies were addressed by a joint re-evaluation of the article with other 
two investigators (NV and EM). 
 
2.5 Statistical Analysis 
The meta-analysis was performed using Review Manager (RevMan) Version 5.3 for Windows 
(Cochrane Collaboration, http://ims.cochrane.org/revman). Only outcomes with at least two studies 
were meta-analyzed, while outcomes with only one study were reported in the descriptive analyses. 
When combining studies, the random effects model was used to account for study heterogeneity 
[16] using standardized mean difference (SMD) with its 95% confidence interval (CI).  
Study heterogeneity was measured using the chi-squared and I-squared statistics, with chi-squared 
p≤0.05 and I-squared ≥50% indicating the presence of significant heterogeneity. [16] For significant 
outcomes including ≥4 studies and with significant heterogeneity, we conducted a meta-regression 
analysis to explore if some variables of the characteristics of the all sample/study or differences in 
some characteristics between those having sarcopenia and those without were significant 
moderators. Publication bias was assessed with a visual inspection of funnel plots and with the 
Begg-Mazumdar Kendall's tau [17] and Egger bias test [18] for outcomes having at least 4 studies. 
Meta-regression and publication bias analyses were conducted using Comprehensive Meta-Analysis 
V3 (http://www.meta-analysis.com/index.php).  
3. Results 
The search identified 1370 potentially eligible studies, of which 354 duplicates were excluded due 
to duplication. After excluding 978 papers through title and abstract review, 38 full text articles 
were examined. Altogether, 19 studies were included in the qualitative synthesis [11], [19]–[36] and 
17 in meta-analysis [20]–[36] (eFigure 1).  
 
3.1 Study and Patient Characteristics 
Studies and patients characteristics are summarized in eTable 1. The 17 meta-analyzed studies 
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[20]–[36]  included a total of 11249 participants (3072 with sarcopenia and 8177 without).  The 
majority of the studies were conducted in Asia and among outpatients (eTable 1). All of the studies 
were published in the last five years.  
Sarcopenic subjects had a mean age of 66.3±6.9 years, a mean BMI of 20.7±3.4 and were slightly 
higher proportion of men  (51.5%).  People without sarcopenia were a mean age of  66.2±6.5 years, 
had a mean BMI of  25.4±2.7 and just over half of the proportion were men (51%) (eTable 1).   
STROBE quality indicators (eTable 2) indicated that only poor information about clearly defined 
exposure ascertainment could be a potential source of bias being present in two studies among 
seventeen [20], [33] included in our meta-analysis. However, for these studies we obtained 
additional data from the Authors, hence detail was not addressed in the primary paper.  
 
3.2 Cross-sectional studies reporting on serum CRP, IL6 and TNF- levels 
Pooling data from 16 studies [20]–[33], [35], [36], people with sarcopenia (n=3391) were 
significantly more likely than those without sarcopenia (n=7658) to have significantly higher levels 
of CRP (SMD=0.51; 95%CI: 0.26, 0.77; p<0.0001; I2=96%) (Figure 1). On the contrary, serum IL6 
levels did not differ between people with sarcopenia (n=1113) versus those with sarcopenia 
(n=1981)  (7 studies [22], [26], [29], [30], [33]–[35]; SMD=0.35; 95%CI: -0.19, 0.89; p=0.21; 
I2=97%) (Figure 2). Similarly, people with sarcopenia (n=1031) had similar levels of TNF-
compared to those without sarcopenia (n=1767) (5 studies [22], [26], [29], [33], [35] ; 
SMD=0.28; 95%CI: -0.26, 0.83; p=0.31; I2=97%) (Figure 3).  
 
3.3 Meta-regression analysis 
Since the analysis investigating CRP as outcome was significant, but had a high heterogeneity 
(I2=96%, p<0.0001), we conducted meta-regression analyses in order to detect potential moderators 
of this heterogeneity. As reported in eTable 3, only the country in which the study was conducted 
(=0.64; 95%CI 0.24, 1.03 p=0.0016; R2=0.54) and the differences in the percentage of females 
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between people with and without sarcopenia (=-0.04; 95%CI 0.02, 0.05, p<0.0001; R2=0.76, 
eFigure 3) emerged as potential moderators of the heterogeneity.  
After stratifying for country (Europe+America vs. Asia), median of sample size (=177) and setting 
(community-dwelling vs. other settings), however, CRP remained significantly higher in those with 
sarcopenia vs. those without although SMD resulted larger in studies made in Asia and in studies 
with more than 177 participants (eTable 4).  
 
3.4 Publication Bias 
As seen in funnel plots (eFigure 3) and confirmed by the Begg’s (tau=0.68, p=0.46) and Egger’s 
test (intercept=5.84±2.54, p=0.31), no publication bias was evident for CRP, no publication bias 
emerged for both IL6 (tau=0.84, p=0.74; Egger’s=1.28±0.84, p=0.24) or TNF-(tau=0.21, p=0.14; 
Egger’s=2.74±1.54, p=0.44) .   
 
3.5 Descriptive findings 
One study [19] reported a no significant difference in monocyte chemoattractant protein-1 (MCP-1) 
between sarcopenic and no sarcopenic subjects, whereas in a prospective, population-based study 
suggest higher levels of IL-6 and CRP increase the risk of muscle strength loss in older men and 
women [11].  
4. Discussion 
In this meta-analysis, involving 3072 people with sarcopenia  and 8177 controls, we found evidence 
suggesting a significantly elevated inflammatory marker profile in people with sarcopenia.  To the 
best of our knowledge, this is the first meta-analysis to investigate the possible relationship between 
sarcopenia and inflammation. Specifically, patients with sarcopenia experienced significantly higher 
levels of CRP, whilst no significant differences emerged for IL6 and TNF-compared to controls.  
Although the analysis investigating CRP as outcome was characterized by a high heterogeneity, we 
9 
 
explained the majority of this with our meta regression analyses. 
 
Surprisingly, sarcopenia was associated with higher serum CRP levels, but not with higher IL6 or 
TNF-compared to the controls. These findings are in agreement with our recent work regarding 
the relationship between frailty and inflammation [37] showing that CRP is more strictly related to 
frailty than IL6 and TNF-Whilst the exact reason for this difference is not clear, it might by 
hypothesized that the number of studies and participants (more limited for IL6 and TNF-could 
play a role in these findings. Although our findings should be clarified and further explored with 
future longitudinal studies, our results support the notion that CRP could be a potential parameter 
for detecting sarcopenia.   
 
Contrary to our findings, a previous narrative review [12] distinguished sarcopenia and cachexia, 
which is  defined as a multifactorial syndrome accompanied by anorexia and loss of muscle mass 
not fully reversed by nutritional support [38]. The authors, hypothesed that sarcopenia may result 
from other mechanisms such as age related decline in hormones, neurodegenerative processes and 
disability, but not necessarily from inflammation [12]. Nevertheless, according with a different and 
emerging research and consistent with our results, sarcopenia may be associated and even caused by 
inflammation albeit of a lesser degree compared to cachexia. Thus, the inflammatory response 
driven by the underlying disease is thought to be very prominent in cachexia whilst seems to be 
lower and chronic in sarcopenia, but finally leading, in both syndromes, to muscle proteolysis and 
myocyte apoptosis [39], [40]. The positive association between sarcopenia and inflammatory 
parameters is also in agreement with a study from Visser et al. who demonstrated that inflammatory 
parameters were inversely related to handgrip strength [10]. Our findings may suggest that the 
plasma titre of some inflammatory molecules could be related to the aspects of muscle decline and 
function impairment; whether this association could be clinically relevant is controversial since the 
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phenotypical and pathophysiological complexity of sarcopenia could not be captured by single 
biological biomarkers but probably need a multidimensional approach [41]. 
 
Moreover, our meta-regression analysis suggests an important role of female gender in explaining 
the association between inflammation and sarcopenia. This finding seems to be pertinent with the 
current literature suggesting that female gender is characterized by higher inflammatory levels than 
men. [42] 
There is growing interest in effective therapies to counteract the catabolic effect of chronic 
inflammation even if it is still limited to animal and in vitro models. Rieu and colleagues showed 
that the development of low grade inflammation may be controlled by an NSAID and the muscle 
protein synthesis restored in the postprandial state in old rats [43]. After 5 months, cytokines levels 
were significantly improved and muscle wasting significantly decreased in rats supplemented with 
ibuprofen compared to controls. The authors suggested that even a mild increase in cytokines 
production make the signalling pathways insensitive to food intake [43]. Moreover, NSAIDs appear 
to have a protective effect against muscle breakdown also in elderly people [44], but there are no 
sufficient data yet and further investigations may be warranted.  
Whilst the current meta-analysis is a first, the findings should be considered along with its 
limitations. The most important of these lies in that the diagnosis of sarcopenia is mainly based only 
on muscular mass parameters, while current guidelines suggest that for this condition both physical 
performance and muscular mass should be decreased for a correct diagnosis of sarcopenia. 
Therefore, we were not able to investigate the association between physical function and 
inflammation. Second, the evidence relies substantially on data from cross-sectional studies, thus 
precluding any suggestion of causation. We included only one study in our meta-analysis dealing 
with the loss of handgrip strength and not with sarcopenia. Thus, future longitudinal research should 
seek to disentangle the directionality of the sarcopenia and inflammation.  Another limitation is the 
high heterogeneity found in almost all the outcomes included. Although we were able to partially 
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explain the heterogeneity affecting the differences in CRP levels between sarcopenic and control 
subjects, other factors are probably important. Finally, we did not assess any intracellular markers 
of inflammation that could be highly related to serum parameters.   
 
In conclusion, our meta-analysis found evidence that sarcopenia is associated with higher serum 
inflammatory parameters and in particular increased CRP levels. Future longitudinal research is 
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Figure 1. Forrest plot of serum high sensitivity C-reactive protein (CRP) in sarcopenic vs. no 
sarcopenic subjects  
 
Abbreviations: SD: standard deviation; CI: confidence interval.  
 
Figure 2. Forrest plot of serum interleukin 6 (IL6) in sarcopenic vs. no sarcopenic subjects. 
 




Figure 3. Forrest plot of serum tumor necrosis factor alpha (TNF-) in sarcopenic vs. no 
sarcopenic subjects. 
 
Abbreviations: SD: standard deviation; CI: confidence interval.  
 
 
 
 
 
 
